Epilepsia:抗癫痫药物治疗可增加血管风险

2011-11-24 MedSci原创 MedSci原创

最新研究发现,长期接受老一代抗癫痫药物(AED)治疗的癫痫症患者发生动脉粥样硬化的风险可能会增加,这是一种常见的动脉硬化疾病。根据目前发表在“国际抗癫痫联盟(International League Against Epilepsy,ILAE)”的期刊《Epilepsia》上的研究发现,血管风险与抗癫痫药物单一治疗的持续时间之间存在着显著的联系。 虽然大多数癫痫患者取得了很好的治疗效果,但是,超

最新研究发现,长期接受老一代抗癫痫药物(AED)治疗的癫痫症患者发生动脉粥样硬化的风险可能会增加,这是一种常见的动脉硬化疾病。根据目前发表在“国际抗癫痫联盟(International League Against Epilepsy,ILAE)”的期刊《Epilepsia》上的研究发现,血管风险与抗癫痫药物单一治疗的持续时间之间存在着显著的联系。

虽然大多数癫痫患者取得了很好的治疗效果,但是,超过30%的患者即使接受抗癫痫药物治疗也会继续出现癫痫症状。这些顽固性癫痫症病例患者需要接受长期或者终身抗癫痫药物治疗。持续时间很长的治疗可能会导致糖尿病、甲状腺问题、精神疾病问题和药物不良反应。先前的研究表明,诸如苯妥英、卡马西平、苯巴比妥和丙戊酸等老一代抗癫痫药物可能会改变代谢途径,导致血管风险的提高。

来自台湾高雄长庚纪念医院的第一作者庄曜聪博士及其同事比较了不同类别抗癫痫药物单一治疗对动脉粥样硬化发展的长期影响。该研究小组招募了接受两年以上的抗癫痫药物单一治疗的160名成年癫痫症患者,以及60名身体健康的对照组志愿者。采用超声波检查方法测定参与者的颈总动脉(CCA)内中膜厚度(IMT),测定值用来评估动脉粥样硬化的程度。

“我们的研究发现,接受长期接受苯妥英、卡马西平和丙戊酸单一治疗的癫痫症患者的颈总动脉(CCA)内中膜厚度(IMT)显著增加”,庄博士说道, “长期抗癫痫药物治疗所导致的这些循环标记的变化,可能会加速动脉粥样硬化过程。”分析显示,颈总动脉(CCA)内中膜厚度(IMT)与抗癫痫药物治疗的持续时间呈正相关。

研究人员还调查了与抗癫痫药物治疗种类相关的具体血管风险因素。长期接受卡马西平或者苯妥英治疗的癫痫症患者,其胆固醇、氨基酸和总同型半胱氨酸的水平都所有所提高,而叶酸的水平则下降,这些都增加了不良心脑血管事件的风险。接受丙戊酸治疗的患者,其尿酸、总同型半胱氨酸和硫代巴比妥酸反应物的水平都所有所提高,该研究的作者认为,基于氧化机制,这会增加提高动脉粥样硬化的风险。

研究表明,应小心谨慎地为需要长期抗癫痫药物治疗的癫痫症患者选择药物,特别是老年患者或者发生血管事件的风险较高的患者。庄博士总结道,“更新的抗癫痫药物,比如拉莫三嗪,可以将代谢紊乱降到最低,因而可以降低长期抗癫痫药物治疗所导致的动脉粥样硬化的风险。”(生物谷Bioon.com)

Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis

Yao-Chung Chuang, Hung-Yi Chuang, Tsu-Kung Lin, Chiung-Chih Chang, Cheng-Hsien Lu, Wen-Neng Chang, Shang-Der Chen, Teng-Yeow Tan, Chi-Ren Huang, Samuel H. H. Chan

Long-term therapy with antiepileptic drugs (AEDs) has been associated with metabolic consequences that lead to an increase in risk of atherosclerosis in patients with epilepsy. We compared the long-term effects of monotherapy using different categories of AEDs on markers of vascular risk and the atherosclerotic process. One hundred sixty adult patients who were receiving AED monotherapy, including two enzyme-inducers (carbamazepine, CBZ; and phenytoin, PHT), an enzyme-inhibitor (valproic acid, VPA), and a noninducer (lamotrigine, LTG) for more than 2 years, and 60 controls were enrolled in this study. All study participants received measurement of common carotid artery (CCA) intima media thickness (IMT) by B-mode ultrasonography to assess the extent of atherosclerosis. Other measurements included body mass index, and serum lipid profile or levels of total homocysteine (tHcy), folate, uric acid, fasting blood sugar, high sensitivity C-reactive protein (hs-CRP), or thiobarbituric acid reactive substances (TBARS). Long-term monotherapy with older-generation AEDs, including CBZ, PHT, and VPA, caused significantly increased CCA IMT in patients with epilepsy. After adjustment for the confounding effects of age and gender, the CCA IMT was found to be positively correlated with the duration of AED therapy. Patients with epilepsy who were taking enzyme-inducing AED monotherapy (CBZ, PHT) manifested disturbances of cholesterol, tHcy or folate metabolism, and elevation of the inflammation marker, hs-CRP. On the other hand, patients on enzyme-inhibiting AED monotherapy (VPA) exhibited an increase in the levels of uric acid and tHcy, and elevation of the oxidative marker, TBARS. However, no significant alterations in the markers of vascular risk or CCA IMT were observed in patients who received long-term LTG monotherapy.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=10644, encodeId=d42d1064404, content=拉莫三嗪真是好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Sat Jul 26 12:51:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082317, encodeId=2a19208231e54, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 06 01:29:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007636, encodeId=5e0e200e63641, content=<a href='/topic/show?id=5de3689ef8' target=_blank style='color:#2F92EE;'>#EPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6897, encryptionId=5de3689ef8, topicName=EPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Jan 31 07:29:00 CST 2012, time=2012-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715999, encodeId=be551e1599944, content=<a href='/topic/show?id=a4175555e85' target=_blank style='color:#2F92EE;'>#抗癫痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55557, encryptionId=a4175555e85, topicName=抗癫痫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=695a32117432, createdName=shuangle, createdTime=Sat Apr 14 20:29:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414684, encodeId=a7541414684cb, content=<a href='/topic/show?id=94a85555919' target=_blank style='color:#2F92EE;'>#抗癫痫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55559, encryptionId=94a85555919, topicName=抗癫痫药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05ca3082114, createdName=mgqwxj, createdTime=Sat Nov 26 10:29:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
    2014-07-26 chen111111

    拉莫三嗪真是好药

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=10644, encodeId=d42d1064404, content=拉莫三嗪真是好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Sat Jul 26 12:51:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082317, encodeId=2a19208231e54, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 06 01:29:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007636, encodeId=5e0e200e63641, content=<a href='/topic/show?id=5de3689ef8' target=_blank style='color:#2F92EE;'>#EPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6897, encryptionId=5de3689ef8, topicName=EPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Jan 31 07:29:00 CST 2012, time=2012-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715999, encodeId=be551e1599944, content=<a href='/topic/show?id=a4175555e85' target=_blank style='color:#2F92EE;'>#抗癫痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55557, encryptionId=a4175555e85, topicName=抗癫痫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=695a32117432, createdName=shuangle, createdTime=Sat Apr 14 20:29:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414684, encodeId=a7541414684cb, content=<a href='/topic/show?id=94a85555919' target=_blank style='color:#2F92EE;'>#抗癫痫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55559, encryptionId=94a85555919, topicName=抗癫痫药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05ca3082114, createdName=mgqwxj, createdTime=Sat Nov 26 10:29:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=10644, encodeId=d42d1064404, content=拉莫三嗪真是好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Sat Jul 26 12:51:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082317, encodeId=2a19208231e54, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 06 01:29:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007636, encodeId=5e0e200e63641, content=<a href='/topic/show?id=5de3689ef8' target=_blank style='color:#2F92EE;'>#EPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6897, encryptionId=5de3689ef8, topicName=EPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Jan 31 07:29:00 CST 2012, time=2012-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715999, encodeId=be551e1599944, content=<a href='/topic/show?id=a4175555e85' target=_blank style='color:#2F92EE;'>#抗癫痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55557, encryptionId=a4175555e85, topicName=抗癫痫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=695a32117432, createdName=shuangle, createdTime=Sat Apr 14 20:29:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414684, encodeId=a7541414684cb, content=<a href='/topic/show?id=94a85555919' target=_blank style='color:#2F92EE;'>#抗癫痫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55559, encryptionId=94a85555919, topicName=抗癫痫药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05ca3082114, createdName=mgqwxj, createdTime=Sat Nov 26 10:29:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
    2012-01-31 lq1767
  4. [GetPortalCommentsPageByObjectIdResponse(id=10644, encodeId=d42d1064404, content=拉莫三嗪真是好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Sat Jul 26 12:51:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082317, encodeId=2a19208231e54, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 06 01:29:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007636, encodeId=5e0e200e63641, content=<a href='/topic/show?id=5de3689ef8' target=_blank style='color:#2F92EE;'>#EPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6897, encryptionId=5de3689ef8, topicName=EPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Jan 31 07:29:00 CST 2012, time=2012-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715999, encodeId=be551e1599944, content=<a href='/topic/show?id=a4175555e85' target=_blank style='color:#2F92EE;'>#抗癫痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55557, encryptionId=a4175555e85, topicName=抗癫痫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=695a32117432, createdName=shuangle, createdTime=Sat Apr 14 20:29:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414684, encodeId=a7541414684cb, content=<a href='/topic/show?id=94a85555919' target=_blank style='color:#2F92EE;'>#抗癫痫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55559, encryptionId=94a85555919, topicName=抗癫痫药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05ca3082114, createdName=mgqwxj, createdTime=Sat Nov 26 10:29:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=10644, encodeId=d42d1064404, content=拉莫三嗪真是好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2d2103784, createdName=chen111111, createdTime=Sat Jul 26 12:51:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082317, encodeId=2a19208231e54, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 06 01:29:00 CST 2012, time=2012-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007636, encodeId=5e0e200e63641, content=<a href='/topic/show?id=5de3689ef8' target=_blank style='color:#2F92EE;'>#EPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6897, encryptionId=5de3689ef8, topicName=EPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Jan 31 07:29:00 CST 2012, time=2012-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715999, encodeId=be551e1599944, content=<a href='/topic/show?id=a4175555e85' target=_blank style='color:#2F92EE;'>#抗癫痫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55557, encryptionId=a4175555e85, topicName=抗癫痫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=695a32117432, createdName=shuangle, createdTime=Sat Apr 14 20:29:00 CST 2012, time=2012-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414684, encodeId=a7541414684cb, content=<a href='/topic/show?id=94a85555919' target=_blank style='color:#2F92EE;'>#抗癫痫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55559, encryptionId=94a85555919, topicName=抗癫痫药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05ca3082114, createdName=mgqwxj, createdTime=Sat Nov 26 10:29:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]

相关资讯

NEJM:儿童期癫痫发作者的长期死亡率

  背景 有关癫痫患儿长期死亡率的前瞻性随访、特征明确的队列研究还很少。我们报告了一个芬兰队列中儿童期被诊断为癫痫受试者的长期死亡率。   方法 我们在一个包括245例1964年有癫痫诊断患儿的基于人群的队列中,评估了癫痫发作的转归和死亡率。该队列被前瞻性随访了40年。我们估计了突然且原因不明的死亡率。该队列中极高的尸检率使我们在几乎所有的研究对象中作出了明确的诊断。   结果 60例受试